Skip to content

Clinical trials

Phase 2 Anemia, Hemolytic, Autoimmune trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Anemia, Hemolytic, Autoimmune Phase: Phase 2 Clear all

19 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20051
20111
20122
20131
20171
20181
20191
20202
20212
20221
20232
20251
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed8
Recruiting3
Not yet recruiting2
Active, not recruiting2
Unknown status2
Terminated1
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Institute of Hematology & Blood Diseases Hospital, China3
Gruppo Italiano Malattie EMatologiche dell'Adulto2
Peking Union Medical College Hospital2
Apellis Pharmaceuticals, Inc.1
Bing Han1
Centre Hospitalier Universitaire Dijon1
City of Hope Medical Center1
Helse Fonna1
Incyte Corporation1
Johns Hopkins University1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Anemia, Hemolytic, Autoimmune19
Hemolysis5
Anemia4
Hematologic Diseases3
Purpura, Thrombocytopenic, Idiopathic3
Autoimmune Diseases2
Leukemia, Lymphocytic, Chronic, B-Cell2
Anemia, Hemolytic1
Felty Syndrome1
Hereditary Sensory and Autonomic Neuropathies1

Trials

Showing 51 to 19 of 19. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.